SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Algorand is a scalable, secure, and decentralized digital currency and smart contract platform. Its protocol uses a variation of Proof-of-Stake (PoS) called Pure PoS (PPoS) to secure the network and reach consensus on block production. Developers can build decentralized applications (dApps) using familiar programming languages, including Python, which Algorand supports natively. Its infrastructure enables various use cases, including payment systems, digital identity solutions, supply-chain tracking, and financial services. The protocol's architecture allows for tokenization of assets and the development of smart contracts, while its technical specifications support both retail users seeking basic transaction capabilities and enterprises requiring more, complex, blockchain solutions.

Algorand

Algorand is currently a major focal point for traders due to its recent surge in social media volume and discussion surrounding its post-quantum security features. Community members remain polarized, with many debating the impact of institutional-grade infrastructure upgrades and potential regulatory shifts while long-term holders focus on accumulation during significant price volatility.

Avalo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the treatment of immune dysregulation by developing therapies that target the LIGHT-signaling network. It also focuses on reducing LIGHT levels which can moderate immune dysregulation in many acute and chronic inflammatory disorders. The company was founded by Blake M. Paterson, Isaac Blech, Barbara S. Slusher, and Solomon H. Snyder on January 31, 2011 and is headquartered in Wayne, PA.

Avalo Therapeutics Inc

Avalo Therapeutics is attracting significant attention as investors monitor its lead clinical candidate, AVTX-009, with the community actively discussing potential Phase 2 trial readouts and bullish analyst coverage that underscores its long-term upside. Market participants are closely watching the high trading volume and volatility, while simultaneously expressing caution over the companys ongoing capital requirements and historical dependence on successful clinical data.

Petróleo Brasileiro SA engages in oil and gas exploration, production, and distribution activities. It operates through the following segments: Exploration and Production; Refining, Transportation, and Marketing; and Gas and Low Carbon Energies. The Exploration and Production segment covers the activities of exploration, development, and production of crude oil, natural gas liquid, and natural gas, for the primary purpose of supplying its domestic refineries. The Refining, Transportation, and Marketing segment refers to refining, logistics, transport, and trading of crude oil and oil products activities as well as exports of ethanol. The Gas and Low Carbon Energies represents the activities of logistic and trading of natural gas and electricity, transportation and trading of liquefied natural gas, generation and electricity by means of thermoelectric power plants, as well as holding interests in transporters and distributors of natural gas. The company was founded on October 3, 1953 and is headquartered in Rio de Janeiro, Brazil.

Petroleo Brasileiro S.A. Petrobras - ADR

Petroleo Brasileiro

Petroleo Brasileiro (PBR) is trending as investors weigh strong production milestones and offshore expansion plans against ongoing concerns regarding political interference and fluctuating oil price environments. The community remains focused on the stock's potential for significant dividend payouts and its status as a value play, while closely monitoring geopolitical risks and regulatory hurdles affecting its deepwater drilling prospects.

United Parcel Service, Inc. is a package delivery company, which engages in the provision of global supply chain management solutions. It operates through the following segments: U.S. Domestic Package, International Package, and Supply Chain Solutions. The U.S. Domestic Package segment includes time-definite delivery of letters, documents, and packages. The International Package segment focuses on delivery and shipments in Europe, Asia, the Indian sub-continent, the Middle East, Africa, Canada, and Latin America. The Supply Chain Solutions is involved in forwarding, logistics, Coyote, Marken, and UPS Mail Innovations. The company was founded by James E. Casey and Claude Ryan on August 28, 1907 and is headquartered in Atlanta, GA.

United Parcel Service, Inc. - Ordinary Shares - Class B

United Parcel Service, Inc.

UPS is currently a major focus for traders as the stock attempts a recovery following a multi-year downtrend, with community sentiment split between those viewing it as a deep-value turnaround play and others concerned about long-term margin pressure from labor costs and losing Amazon volume. Investors are actively monitoring the stock's consolidation around the $100 level, looking for signs that restructuring efforts and cost-cutting can successfully defend the dividend and drive a sustained breakout.

ARK ETF Trust - ARK Innovation ETF

ARK Innovation ETF

The ARK Innovation ETF is seeing heightened volatility as investors weigh the impact of shifting rate expectations and rotation out of speculative growth assets. Community discussion is sharply divided between those tracking Cathie Wood's tactical shifts in and out of crypto-linked stocks and critics focusing on the fund's long-term performance struggles.

The Internet Computer is a decentralized cloud blockchain designed to run applications, websites, and backend systems fully on-chain. Its architecture provides robust security, resilience, and built-in multi-chain support.  A key focus of the network is enabling a “self-writing cloud,” where AI tools allow users generate applications through natural-language instructions.  Developers and users can experiment with the platform using AI app-generation tools like caffeine.ai or by writing serverless code directly through online IDEs such as icp.ninja.  The ICP token is used to pay for computation (through a burn-based model) and to participate in network governance through staking.

Internet Computer

Internet Computer (ICP) is currently a focal point for the community due to major structural updates like Mission 70aimed at reducing token inflationand increasing adoption through sovereign subnets in regions like Switzerland and Pakistan. While some users remain skeptical due to historical volatility and the project's long-term performance, many community members are highlighting the real-world utility of platforms like Caffeine.ai and the growing number of canisters as indicators that the network's fundamentals are strengthening for a future recovery.

Aurinia Pharmaceuticals, Inc. is a clinical stage bio-pharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Edmonton, Canada.

Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals is trending following a major management shake-up where long-time CEO Peter Greenleaf was replaced by board chair Kevin Tang, a move that investors view as a pivotal step toward unlocking shareholder value and accelerating potential acquisition efforts. The community is actively discussing the leadership transition, Tang's significant investment with no compensation, and the expectation that the new team will prioritize a strategic sale or partnership.

FLOKI is a community-driven, multi-chain utility token that powers a broad ecosystem including decentralized gaming, finance, and educational platforms. Originally evolving from a meme-based asset, the project now focuses on a utility-driven model centered around three pillars: community engagement, technical utility, and global charity work, balancing this ecosystem growth with social impact, such as building schools in developing nations like Ghana and Nigeria.  Key features include Valhalla, an NFT metaverse game where the token serves as the primary currency for capturing creatures and upgrading characters. The ecosystem also features the FlokiFi Locker for securing digital assets and the University of FLOKI for web3 education,with real-world integration facilitated through a prepaid debit card for everyday purchases at global stores. Staking FLOKI allows users to earn rewards in a sister token.  The project is led by a group of core advisors known by pseudonyms such as Sabre and B (The Viking) and is officially backed by DWF Labs, a major digital asset investment firm and market maker. While a small tax on decentralized trades helps fund development, value moves through the system as users utilize the token to pay for in-game items, access asset-locking services, or purchase merchandise.

Floki Token

$FLOKI is seeing increased activity as the community celebrates the launch of its ETP in Europe, which is being viewed as a significant milestone for institutional accessibility. Traders are currently split between long-term optimism about the token's ecosystem developmentssuch as gaming and DeFi toolsand frustration over recent price volatility that has left many questioning the current market trend.

Astera Labs, Inc. is a global semiconductor company, which engages in the provision of hardware and software solutions for AI and cloud infrastructure applications to solve data, memory, and networking bottlenecks. It operates through the following geographical segments: Taiwan, China, United States, and Other. The company was founded by Jitendra Mohan, Casey Morrison, and Sanjay Gajendra in October 2017 and headquartered in San Jose, CA.

Astera Labs Inc.

Astera Labs Inc

Astera Labs is currently experiencing heightened volatility and intense community scrutiny following a sharp share price decline triggered by analyst downgrades and broader tech sector rotation, despite a significant new partnership agreement with Amazon. Investors are actively debating whether this pullback represents an attractive long-term buying opportunity or a deeper structural issue, with many focusing on the company's role as a critical link in the AI infrastructure build-out.

Clene, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology therapeutics. It offers a nanotechnology drug platform for the development of a new class of orally administered neurotherapeutic drugs. The company was founded in 2013 and is headquartered in Salt Lake City, UT.

Clene Inc

Clene Inc. is trending as the community eagerly awaits definitive biomarker data and regulatory updates regarding an accelerated approval pathway for its ALS candidate, CNM-Au8. Investors are closely monitoring upcoming conference presentations and regulatory milestones, balancing high-conviction long-term sentiment against volatility driven by short interest and recent insider selling activity.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Palisade Bio Shares Phase 1b PALI-2108 Data Showing Safety, PK and Early Crohn's Efficacy Signals

Palisade Bio (NASDAQ:PALI) said it generated encouraging safety, pharmacokinetic and early efficacy signals from an open-label Phase 1b study of PALI-2108 in fibrostenotic Crohn's disease, a difficult-to-treat population where patients often progress from inflammation to structural fibrosis and may...

HC Wainwright Forecasts Palisade Bio Q1 Earnings

Palisade Bio, Inc. (NASDAQ:PALI - Free Report) - Research analysts at HC Wainwright issued their Q1 2026 earnings per share estimates for shares of Palisade Bio in a research report issued on...

HC Wainwright Begins Coverage on Palisade Bio (NASDAQ:PALI)

HC Wainwright started coverage on Palisade Bio in a research report on Thursday. They issued a "buy" rating and a $7.00 price objective for the company...

Palisade Bio (NASDAQ:PALI) Issues Quarterly Earnings Results, Beats Estimates By $1.10 EPS

Palisade Bio (NASDAQ:PALI - Get Free Report) released its quarterly earnings results on Friday. The company reported $1.08 EPS for the quarter, beating the consensus estimate of ($0.02) by $1.10...

Palisade Bio, Inc. (NASDAQ:PALI) Receives Consensus Recommendation of "Moderate Buy" from Analysts

Shares of Palisade Bio, Inc. (NASDAQ:PALI - Get Free Report) have earned a consensus rating of "Moderate Buy" from the seven brokerages that are currently covering the stock, MarketBeat.com reports...

Palisade Bio (PALI) Expected to Announce Quarterly Earnings on Monday

Palisade Bio (NASDAQ:PALI) will be releasing its Q4 2025 earnings before the market opens on Monday, March 23. (View Earnings Report at...

Short Interest in Palisade Bio, Inc. (NASDAQ:PALI) Rises By 20.2%

Palisade Bio, Inc. (NASDAQ:PALI - Get Free Report) saw a large increase in short interest during the month of February. As of February 13th, there was short interest totaling 25,352,984 shares, an...

Palisade Bio Details PALI-2108 UC, Crohn's Plans and Cash Runway Into 2029 at Oppenheimer Conference

Palisade Bio (NASDAQ:PALI) executives outlined the company's strategic pivot, lead development priorities, and financing position during a fireside chat at Oppenheimer's 36th Annual Healthcare Life...

Palisade Bio (NASDAQ:PALI) Upgraded to "Hold" at Wall Street Zen

Wall Street Zen raised Palisade Bio from a "sell" rating to a "hold" rating in a report on Saturday...

Palisade Bio (NASDAQ:PALI) Now Covered by Stifel Nicolaus

Stifel Nicolaus began coverage on Palisade Bio in a report on Wednesday. They set a "buy" rating and a $5.00 price objective on the stock...

This account has been verified as an official PALI representative.

Verified Account

Palisade Bio

Palisade Bio, Inc. is a biopharmaceutical company, which engages in the development of oral therapies that help patients with acute and chronic gastrointestinal complications stemming from post-operative digestive enzyme damage. It offers LB1148, an oral formulation of a broad-spectrum serine protease inhibitor designed to neutralize the activity of potent digestive proteases released from the gut during surgery. The company was founded on September 6, 2011 and is headquartered in Carlsbad, CA.

Palisade Bio Inc

Opendoor ($OPEN)

Strategy ($MSTR)

American Eagle ($AEO)

Ondas Inc. ($ONDS)

The stock that proved the power of the crowd. Fueled by community energy and social momentum, this winner captivated retail investors regardless of what the "experts" or traditional fundamentals had to say.

Current Price	$1.89
Prev Close	$1.88
Open	$1.85
Dividend Yield	0.00%
50-Day Moving Average	$1.79
Beta	1.01
Avg. Volume	3.97M
PE Ratio	-1.27

52-Week High	$2.64
52-Week Low	$0.53
Market Capitalization	$313.52M
EPS (Annual)	-$0.3014
Price to Book	2.33
Revenue Per Employee	$0.00

PALI
Palisade Bio Inc

Feed

News

Sentiment

Fundamentals

Info

Latest PALI News

PALIPalisade Bio Inc